Latest Ratios: P/E Ratio 0.0x · EV/EBITDA N/A · ROE 126.2%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $14M | $34M | $24M | $50M | $72M | $112M | $111M | $73M | $3M | $8M | $17M |
| Enterprise Value | $13M | $33M | $21M | $50M | $30M | $101M | $106M | $69M | $-6882237 | $4M | $10M |
| P/E Ratio → | 0.02 | 0.03 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | 48.76 | — | — | — | — |
| P/B Ratio | 0.01 | 0.02 | 1.02 | 1.67 | 1.28 | 1.31 | 3.13 | 6.43 | 0.29 | 2.48 | 1.90 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | 46.35 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | -12.6% | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | -429.7% | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | -519.3% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 126.2% | 126.2% | -55.9% | -66.9% | -43.8% | -24.0% | -50.6% | -89.4% | -76.2% | -100.2% | -120.3% |
| ROA | 104.9% | 104.9% | -46.5% | -55.6% | -38.2% | -21.4% | -40.8% | -65.6% | -66.9% | -83.4% | -102.9% |
| ROIC | -1.2% | -1.2% | -45.6% | -99.8% | -43.8% | -27.7% | -39.2% | -174.1% | — | -610.1% | -190.8% |
| ROCE | -1.3% | -1.3% | -56.8% | -64.0% | -34.1% | -30.5% | -41.1% | -80.2% | -81.1% | -100.4% | -118.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.02 | 0.03 | 0.09 | 0.01 | 0.01 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.00 | -0.12 | 0.01 | -0.76 | -0.12 | -0.15 | -0.34 | -1.00 | -1.12 | -0.79 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1153.85 | -1153.85 | -1154.92 | -2075.29 | -4.90 | -58.80 | -1630.83 | -1231.29 | — | — | — |
Net cash position: cash ($2M) exceeds total debt ($641000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 193.24 | 193.24 | 6.84 | 5.57 | 7.92 | 18.32 | 8.72 | 2.75 | 9.09 | 7.87 | 5.46 |
| Quick Ratio | 193.24 | 193.24 | 6.84 | 5.57 | 7.74 | 20.91 | 8.72 | 2.50 | 9.09 | 7.87 | 5.46 |
| Cash Ratio | 0.65 | 0.65 | 6.18 | 4.51 | 7.28 | 17.83 | 8.17 | 2.01 | 8.65 | 7.67 | 3.56 |
| Asset Turnover | — | — | — | — | — | — | 0.06 | — | — | — | — |
| Inventory Turnover | — | — | — | — | 0.66 | — | — | 0.20 | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 100.0% | 3624.5% | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $48M | $21M | $19M | $18M | $18M | $13M | $9M | $461028 | $428241 | $397655 |
Imminent liquidity and dilution
Based on reported figures, the company's P/B ratio of 0.01 suggests a significant market-imposed distress discount, as investors appear to heavily discount the firm's intangible-heavy asset base in light of the extremely limited cash runway and the binary nature of its upcoming clinical trial readouts.
The valuation multiples are effectively non-functional due to the absence of revenue and the distortion of accounting equity by large, non-cash intangible assets. Investors should monitor the gap between the book value and the market capitalization, which indicates that the market assigns little to no value to the current pipeline beyond the immediate risk of dilution.
As reported in financial statements, the company's ROIC has consistently trended in negative territory, reaching -0.5% in 2025Q4, which highlights the structural inability of the current R&D-heavy business model to generate positive returns on invested capital prior to achieving commercial viability for its therapeutic candidates.
The persistent negative ROIC reflects the high cost of clinical development relative to the lack of operational output. This trend suggests that capital is being consumed to sustain the organization rather than compounding, which warrants further investigation into the efficiency of the company's R&D spending relative to its peers.
According to recent SEC filings, the company's current ratio of 193.24 in 2025Q4 is misleading, as it masks a critical cash position of only $2 million, which is insufficient to support the ongoing clinical trial infrastructure and operational requirements for the upcoming fiscal year.
The high current ratio is likely a byproduct of accounting anomalies rather than actual liquid strength, as the company's cash-to-burn ratio remains dangerously low. This liquidity profile suggests that the firm is highly vulnerable to even minor operational disruptions or delays in clinical trial milestones.
Based on comparative data, Enlivex lags behind peers like ADMA Biologics, which demonstrates positive margins and ROIC, whereas Enlivex remains trapped in a negative profitability cycle that is characteristic of its high-risk, pre-revenue status within the inflammation-focused cell therapy sector.
The gap between Enlivex and its more established peers is structural, driven by the company's lack of commercialized products and its reliance on external financing. Investors should monitor whether the company can bridge this performance gap through successful clinical data, or if it will continue to underperform the broader biotech peer group.
The P/B ratio is the most commonly misapplied metric for this business model, as it obscures the reality that the company's reported equity is heavily inflated by intangible assets that lack immediate liquidation value in the event of a clinical failure or liquidity crisis.
Relying on P/B to assess value in this context is misleading because it ignores the company's actual cash-based burn rate and the binary risk of its clinical pipeline. Analysts should instead focus on the 'burn-to-zero' timeline and the probability-weighted net present value of the Allocetra platform to better understand the firm's true economic worth.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ENLV stock.
Enlivex Therapeutics Ltd.'s current P/E ratio is 0.0x. The historical average is 0.0x.
Enlivex Therapeutics Ltd.'s return on equity (ROE) is 126.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is -67.8%.
Based on historical data, Enlivex Therapeutics Ltd. is trading at a P/E of 0.0x. Compare with industry peers and growth rates for a complete picture.